Table 1.
Baseline patient characteristics
| N = 293 | Mean ± SE | Patients (%) |
|---|---|---|
| Age (years) | 60.7 ± 0.7 | |
| Gender | ||
| Female | 44 | |
| Male | 56 | |
| Smoking History | ||
| Positive | 53.9 | |
| Negative | 46.1 | |
| ECOG | ||
| 1 | 45.4 | |
| 2 | 23.5 | |
| 3 | 31.1 | |
| Clinical Stage | ||
| III B | 29.4 | |
| IV | 70.6 | |
| Histology | ||
| Adenocarcinoma | 64.8 | |
| *Other | 35.2 | |
| Histological Grade | ||
| Low | 10.3 | |
| Moderate | 35.9 | |
| High | 53.8 | |
| Metastasis at Diagnosis | ||
| CNS | 18.6 | |
| Liver | 7.5 | |
| **Other | 44.9 | |
| First Line Treatment | ||
| Chemotherapy | 87.4 | |
| Tyrosine-kinase inhibitors | 12.6 | |
| EGFR*** | ||
| Positive | 58.6 | |
| Negative | 41.4 | |
| HER2*** | ||
| Positive | 6.8 | |
| Negative | 93.2 |
SE: Standard Error.
ECOG: Eastern Oncology Cooperative Group Scale.
*Other: Squamous, Giant Cells, Undifferentiated.
CNS: Central Nervous System.
**Other: Lymph Nodes, Bones, Contralateral Lung.
EGFR: Epidermal Growth-Factor Receptor.
***: Tissue expression was determined only in 85 different
primary tumor samples (see text).